Savino Sciascia, Maria Letizia Antonietta Rilat, Roberta Fenoglio, Silvia Grazietta Foddai, Massimo Radin, Irene Cecchi, Giacoma Cinnirella, Paola Crosasso, Maria Gabriella Guidetti, Alice Barinotti, Simone Baldovino, Elisa Menegatti, Dario Roccatello
BACKGROUND: Patients on B-cell-depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or suffering from a more severe prognosis. Indeed, available data on pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in subjects with glomerular diseases (GDs) who received rituximab are limited. METHODS: We conducted a prospective study analysing the safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in patients with GDs who received rituximab in the previous 12 months...
September 2023: Clinical Kidney Journal